Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43845   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-001363-12
    Sponsor's Protocol Code Number:TRIANGLE
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2017-10-02
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2014-001363-12
    A.3Full title of the trial
    autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European
    MCL Network trial
    Protocolo TRIANGLE del European MCL Network- Estudio Aleatorizado con Régimen de Inducción Combinando Rituximab/Ibrutinib/ara-C seguido de Trasplante Autólogo en Linfoma de Células del Manto Diseminado
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European
    MCL Network trial
    Protocolo TRIANGLE del European MCL Network- Estudio Aleatorizado con Régimen de Inducción Combinando Rituximab/Ibrutinib/ara-C seguido de Trasplante Autólogo en Linfoma de Células del Manto Diseminado
    A.3.2Name or abbreviated title of the trial where available
    TRIANGLE
    TRIANGLE
    A.4.1Sponsor's protocol code numberTRIANGLE
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorKlinikum der Universität München, Medizinische Klinik und Poliklinik III
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportJanssen Pharmaceutica NV
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGrupo Español de linfoma y trasplante de medula osea (GELTAMO)
    B.5.2Functional name of contact pointSecretaria Cientifica de GELTAMO
    B.5.3 Address:
    B.5.3.1Street AddressFortuny, 51, local 5
    B.5.3.2Town/ citymadrid
    B.5.3.3Post code28010
    B.5.3.4CountrySpain
    B.5.4Telephone number+3491319 57 80
    B.5.5Fax number+3491391 33 83
    B.5.6E-mailensayosclinicos01@geltamo.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Imbruvica
    D.2.1.1.2Name of the Marketing Authorisation holderJanssen Research & Development, LCC and Pharmacyclics, LCC
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community Yes
    D.2.5.1Orphan drug designation numberEU/3/12/984 and EU/3/13/1115.
    D.3 Description of the IMP
    D.3.1Product nameIbrutinib
    D.3.2Product code PCI-32765
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNibrutinib
    D.3.9.1CAS number 936563-96-1
    D.3.9.3Other descriptive nameIBRUTINIB
    D.3.9.4EV Substance CodeSUB120863
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number140
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Generalized mantle cell Lymphoma
    Linfoma de Células del Manto Diseminado
    E.1.1.1Medical condition in easily understood language
    Generalized mantle cell Lymphoma
    Linfoma de Células del Manto Diseminado
    E.1.1.2Therapeutic area Diseases [C] - Blood and lymphatic diseases [C15]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10026805
    E.1.2Term Mantle cell lymphoma stage IV
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10026804
    E.1.2Term Mantle cell lymphoma stage III
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10026803
    E.1.2Term Mantle cell lymphoma stage II
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To establish one of three study arms, R-CHOP/R-DHAP followed by ASCT (control arm A), R-CHOP+ibrutinib /R-DHAP followed by ASCT and
    ibrutinib maintenance (experimental armA+I), and R-CHOP+ibrutinib /R-DHAP followed by ibrutinib maintenance (experimental arm I) as
    future standard based on the comparison of the investigator-assessed failure-free survival (FFS).
    Establecer una de los tres grupos del estudio, R-CHOP/R-DHAP seguido de TASPE (grupo control A), R-CHOP+Ibrutinib /R-DHAP seguido de TASPE y mantenimiento con Ibrutinib (grupo experimental A+I), y R-CHOP+Ibrutinib /R-DHAP seguido de mantenimiento con Ibrutinib (grupo experimental I) como futuro tratamiento estándar basado en la comparación de la supervivencia libre de fracaso (SLF) evaluada por el investigador
    E.2.2Secondary objectives of the trial
    To compare the efficacy of the three treatment arms in terms of secondary efficacy endpoints.
    To determine the safety and tolerability of ibrutinib during induction immuno-chemotherapy and during maintenance and to compare the safety profile of the three treatment arms in terms of secondary toxicity endpoints.
    Comparar la eficacia de los tres grupos de tratamiento en términos de las variables secundarias de eficaciaDeterminar la seguridad y tolerabilidad de Ibrutinib durante la inducción con inmunoquimioterapia y durante el mantenimiento y comparar el perfil de seguridad de los tres grupos de tratamiento en términos de la variable secundaria de toxicidad.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Histologically confirmed diagnosis of MCL according to WHO
    classification
    2. suitable for high-dose treatment including high-dose AraC
    3. Stage II-IV (Ann Arbor)
    4. Age >= 18 years and <= 65 years
    5. Previously untreated MCL
    6. At least 1 measurable lesion; in case of bone marrow infiltration only,
    bone marrow aspiration and biopsy is mandatory for all staging
    evaluations.
    7. ECOG/WHO performance status <= 2
    8. The following laboratory values at screening (unless related to MCL):
    - Absolute neutrophil count (ANC) >=1000 cells/uL
    - Platelets >=100,000 cells/uL
    - Transaminases (AST and ALT) <= 3 x upper limit of normal (ULN)
    - Total bilirubin <= 2 x ULN unless due to known Morbus Meulengracht
    [Gilbert-Meulengracht-Syndrome])
    - Creatinine <=2 mg/dL or calculated creatinine clearance >= 50
    mL/min
    9. Written informed consent form according to ICH/EU GCP and national
    regulations
    10. Sexually active men and women of child-bearing potential must
    agree to use one of the highly effective contraceptive methods
    (combined oral contraceptives using two hormones, contraceptive
    implants, injectables, intrauterine devices, sterilized partner) together
    with one of the barrier methods (latex condoms, diaphragms,
    contraceptive caps) while on study; this should be maintained for 90
    days after the last dose of study drug.
    1.Diagnóstico confirmado de linfoma de células del manto de acuerdo a la clasificación de la OMS.
    2.Pacientes candidatos a recibir tratamiento intensivo incluidas dosis altas de Ara-C
    3.Estadios clínicos de Ann Arbor II-IV.
    4.Pacientes ≥ 18 años y ≤ 65 años
    5.Pacientes no tratados previamente para MCL
    6.Al menos una lesión medible, en caso de que solo esté infiltrada la medula ósea, el aspirado y la biopsia de médula ósea son obligatorios para todas las evaluaciones de la enfermedad
    7.Estado general ECOG/OMS ≤ 2
    8. Valores de laboratorio en el screening (a menos que estén relacionados con el MCL):
    o Recuento Absoluto de Neutrófilos (ANC) 1000 células/L
    o Plaquetas 100,000 células/L
    o Transaminasas (AST y ALT) ≤ 3 x límite superior normal (LSN)
    o Bilirrubina total ≤2 x LSN a menos que el aumento de bilirrubina se deba a un síndrome Morbus Meulengracht [Gilbert-Meulengracht-Syndrome])
    o Creatinina ≤ 2 mg/dL o aclaramiento de creatinina calculado ≥ 50 mL/min/
    9. Consentimiento informado por escrito de acuerdo a las normas ICH/EU GCP y la regulación nacional
    10.Hombres sexualmente activos y mujeres en edad fértil tendrán que utilizar uno de los método anticonceptivo altamente eficaces (ej., anticonceptivo oral combinado usando dos hormonas, implantes, inyectables, anticonceptivos orales combinados, dispositivos intrauterinos, o esterilización de la pareja) junto con un método barrera (preservativo, diafragmas, capsulas anticonceptivas) mientras dure su participación en el estudio; y mantenerse de esta forma durante 90 días después de la última dosis del fármaco en estudio.
    E.4Principal exclusion criteria
    1. Major surgery within 4 weeks prior to randomization.
    2. Requires anticoagulation with warfarin or equivalent vitamin K
    antagonists (e.g. phenprocoumon).
    3. History of stroke or intracranial hemorrhage within 6 months prior to
    randomization.
    4. Requires treatment with strong CYP3A4/5 inhibitors.
    5. Any life-threatening illness, medical condition, or organ system
    dysfunction which, in the investigator's opinion, could compromise the
    subject's safety, interfere with the absorption or metabolism of ibrutinib
    capsules, or put the study outcomes at undue risk.
    6. Vaccinated with live, attenuated vaccines within 4 weeks prior to
    randomization.
    7. Known CNS involvement of MCL.
    8. Clinically significant hypersensitivity (e.g., anaphylactic or
    anaphylactoid reactions to the compound of ibrutinib itself or to the
    excipients in its formulation).
    9. Known anti-murine antibody (HAMA) reactivity or known
    hypersensitivity to murine antibodies.
    10. Previous lymphoma therapy with radiation, cytostatic drugs, anti-
    CD20 antibody or interferon except prephase therapy according to trial
    protocol.
    11. Serious concomitant disease interfering with a regular therapy
    according to the study protocol:
    - Cardiac (Clinically significant cardiovascular disease such as
    uncontrolled or symptomatic arrhythmias, congestive heart failure, or
    myocardial infarction within 6 months of Screening, or any Class 3
    (moderate) or Class 4 (severe) cardiac disease as defined by the New
    York Heart Association Functional Classification or LVEF below LLN),
    - Pulmonary (e.g. chronic lung disease with hypoxemia),
    - Endocrinological (e.g. severe, not sufficiently controlled diabetes
    mellitus),
    - Renal insufficiency (unless caused by the lymphoma): creatinine > 2x
    normal value and/or creatinin clearance < 50 ml/min),
    - Impairment of liver function (unless caused by the lymphoma):
    transaminases > 3x normal or bilirubin > 2,0 mg/dl unless due to Morbus Meulengracht (Gilbert-Meulengracht-Syndrome).
    12. Patients with unresolved hepatitis B or C infection or known HIV
    positive infection (mandatory test).
    13.Prior organ, bone marrow or peripheral blood stem cell
    transplantation.
    14. Concomitant or previous malignancies within the last 3 years other
    than basal cell skin cancer or in situ uterine cervix cancer.
    15.Pregnancy or lactation.
    16. Any psychological, familiar, sociological, or geographical condition
    potentially hampering compliance with the study protocol and follow up
    schedule.
    17. Subjects not able to give consent.
    18. Subjects without legal capacity who are unable to understand the
    nature, scope, significance and consequences of this clinical trial.
    19. Participation in another clinical trial within 30 days before
    randomization in this study
    1.Cirugía mayor en las 4 semanas previas a la aleatorización.
    2.Necesidad de anticoagulación con antagonistas de la vitamina K.(ej. acenocumarol, phenprocoumon).
    3.Historia de ictus o hemorragia intracraneal en los 6 meses previos a la inclusión.
    4.Necesidad de tratamiento con inhibidores potentes de CYP3A4/5.
    5.Cualquier enfermedad, condición clínica o disfunción de órganos que, a criterio del investigador, pueda comprometer la seguridad del paciente, interferir con la absorción o metabolismo de las cápsulas de Ibrutinib, o ponga en riesgo los resultados del estudio.
    6.Vacunación con vacunas vivas atenuadas en las 4 semanas previas a la aleatorización.
    7.Infiltración de SNC conocida de MCL
    8.Hipersensibilidad clínicamente significativa (ej., reacciones anafilácticas o anafilactoides al propio compuesto de Ibrutinib o a los excipientes de su formulación)
    9.Reactividad conocida al anticuerpo anti-murino (HAMA) o hipersensibilidad a anticuerpos murinos.
    10.Terapia previa para el linfoma con radiación, medicación citostática, anticuerpos anti-CD20 o interferón excepto la terapia de prefase contemplada en el protocolo del estudio
    11.Enfermedad grave concomitante que interfiera con el tratamiento de acuerdo al protocolo del estudio:
    o Enfermedades cardiovasculares significativas como arritmias no controladas o sintomáticas, insuficiencia cardiaca congestiva, infarto de miocardio en los 6 meses previos al screening, o cualquier enfermedad cardiaca clase 3 (moderada) o clase 4 (severa) como se define por la NYHA o disminución de la fracción de eyección por debajo de la normalidad
    o Enfermedad pulmonar (ej. Enfermedad pulmonar crónica con hipoxemia)
    o Endocrinopatía (ej. grave, diabetes mellitus no suficientemente controlada)
    o Insuficiencia renal (a menos que este causada por el linfoma): creatinina > 2x valor normal y/o aclaramiento de creatinina < 50 ml/min)
    o Alteración de la función hepática (a menos que este causada por el linfoma): transaminasas > 3x valor normal o bilirrubina > 2,0 mg/dl a menos que sea debida a un síndrome de Gilbert
    12. Pacientes con hepatitis B o C activas o infección por VIH (test obligatorio)
    13.Trasplante previo de órgano, medula ósea o sangre periférica
    14.Neoplasias previas o concomitantes en los últimos 3 años, que no sean cáncer de piel (carcinoma basocelular) o cáncer de cuello uterino in situ.
    15.Mujeres embarazadas o en periodo de lactancia
    16.Cualquier condición psicológica, familiar, sociológica o geográfica que potencialmente pueda interferir con el cumplimiento del protocolo y del seguimiento.
    17.Pacientes incapaces de dar consentimiento
    18..Pacientes con capacidades legales reducidas incapaces de comprender la naturaleza, objetivo, significado y consecuencias de este ensayo clínico.
    19.Pacientes que hayan participado en otro ensayo clínico en los 30 días previos a la aleatorización del estudio.
    E.5 End points
    E.5.1Primary end point(s)
    FFS defined as time from start of treatment to stable disease at end of immuno-chemotherapy, progressive disease, or death from any cause.
    SLF definida como el tiempo desde el inicio del tratamiento hasta enfermedad estable al final de la inmunoquimioterapia, progresión de la enfermedad, o fallecimiento por cualquier causa
    E.5.1.1Timepoint(s) of evaluation of this end point
    End of immuno-chemotherapy, progressive disease, or death from any cause
    Final de la inmunoquimioterapia, progresión de la enfermedad, o fallecimiento por cualquier causa
    E.5.2Secondary end point(s)
    Secondary Efficacy Endpoints:
    1. Overall survival (OS).
    2. Progression-free survival (PFS) from randomization, from end of
    induction immuno-chemotherapy in patients with CR or PR at end of
    induction immuno-chemotherapy, and from the staging 6 weeks after
    end of induction assessment (at month 6).
    3. Overall response and complete remission rates at midterm, at end of
    induction, 3 months after end of induction immunochemotherapy (at
    month 6).
    4. PR to CR conversion rate during follow-up after end of induction
    immuno-chemotherapy.
    Secondary Toxicity Endpoints:
    1. Rates of AEs, SAEs, and SUSARs by CTC grade (Version 4.03) during
    induction immuno-chemotherapy and during periods of follow-up after
    response to immune-chemotherapy.
    2. Cumulative incidence rates of SPMs.
    Variables secundarias de eficacia:
    1. Supervivencia global (SG)
    2. Supervivencia libre de progresión (SLP) desde la aleatorización, desde el final de la inducción con inmunoquimioterapia en pacientes que alcanzan RC o RP y tras el periodo de 6 semanas después de finalizar las evaluaciones de la inducción (en el mes 6).
    3. Respuesta global y tasa de remisión completa en la mitad, al final de la inducción, y 3 meses después de la inmunoquimioterapia de inducción (en el mes 6)
    4. Tasa de conversión de RP a RC durante el seguimiento después de finalizar la inducción con inmunoquimioterapia.
    Variables secundarias de toxicidad:
    1.Tasas AEs, SAEs, y SUSARs mediante clasificación CTC (Versión 4.03) durante la inducción con inmunoquimioterapia y durante los periodos de seguimiento después de la respuesta a la inmunoquimioterapia
    2.Incidencia acumulada de segundas neoplasias
    E.5.2.1Timepoint(s) of evaluation of this end point
    Overall survival (OS)
    Progression-free survival (PFS) from randomization, from end of induction immuno-chemotherapy in patients with CR or PR at end of induction immuno-chemotherapy, and from the staging 6 weeks after end of induction assessment (at month 6)
    Overall response and complete remission rates at midterm, at end of induction, 3 months after end of induction immunochemotherapy (at month 6)
    PR to CR conversion rate during follow-up after end of induction immuno-chemotherapy
    Supervivencia global (SG)
    Supervivencia libre de progresión (SLP) desde la aleatorización, desde el final de la inducción con inmunoquimioterapia en pacientes que alcanzan RC o RP y tras el periodo de 6 semanas después de finalizar las evaluaciones de la inducción (en el mes 6).
    Respuesta global y tasa de remisión completa en la mitad, al final de la inducción, y 3 meses después de la inmunoquimioterapia de inducción (en el mes 6)
    Tasa de conversión de RP a RC durante el seguimiento después de finalizar la inducción con inmunoquimioterapia
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Seis ciclos alternos de R-CHOP/RDHAP segudios de TASPE
    Six alternating courses of R-CHOP/RDHAP followed by ASCT
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned14
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA230
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Croatia
    Czech Republic
    Denmark
    Finland
    Germany
    Israel
    Italy
    Netherlands
    Norway
    Poland
    Portugal
    Spain
    Sweden
    Switzerland
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Ultima visita del ultimo paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years10
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years10
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 870
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state70
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 800
    F.4.2.2In the whole clinical trial 870
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients will be treated according to the local standard care.
    Los pacientes serán tratado de acuerdo a la practica habitual
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    G.4.1Name of Organisation Grupo Español de Linfoma y Trasplante de Medula Osea (GELTAMO)
    G.4.3.4Network Country Spain
    G.4 Investigator Network to be involved in the Trial: 2
    G.4.1Name of Organisation Phase I/II platform e.V. of the European Mantle Cell Lymphoma Network, Klinikum der Universität München, Med. Klinik III
    G.4.3.4Network Country Germany
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-12-18
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-12-15
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 18 21:06:35 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA